[Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma].

Objective: To evaluate the effect and adverse effects of arsenic trioxide (As2O3) in the treatment of primary hepatocarcinoma patients, and conduct the pharmacokinetics study.

Methods: A total of one hundred and eleven advanced primary hepatocarcinoma patients in five centers were treated with As2O3 injection 7 - 8 mg/m(2) i.v.